Back to News
Market Impact: 0.2
Myriad Genetics Reaches Analyst Target Price
Source: Nasdaq
Analyst EstimatesAnalyst InsightsMarket Technicals & Flows
Myriad Genetics shares rose above the average 12-month analyst target of $3.31, trading at $3.36 per share. The move places the stock slightly above consensus valuation expectations and could prompt analysts to reassess ratings or price targets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
MYGN0.20
More News
- ‘Worrying Times’ for Bonds as 10-Year Yield Nears 5%
- Surging cloud revenue boosted Oracle’s quarterly results. Here’s what analysts are saying
- Oracle jumps 6% after reporting 30% revenue growth fueled by AI cloud demand
- US Economy Probably Needs Three Fed Rate Hikes, BNP’s Mateos y Lago Says
- Investors brace for possible rate hike at uncertain Fed meeting
- Global Bond Selloff Pushes US 10-Year Treasury Yield Toward 5%